The dysregulation of the Ras/Raf/MEK/ERK pathway in cutaneous neurofibromas, epidermal nevi, nevus sebaceous, and other RASopathies of the skin provides the scientific rationale behind our goal to use MEK inhibitors to treat cutaneous neurofibromas. Like Ras, MEK serves as another crucial link downstream in the chain of proteins that passes the message from a signaling molecule to the cell’s nucleus. By inhibiting the MEK protein component in the Ras/Raf/MEK/ERK pathway, we can restore a means to regulate the signal causing uncontrolled cell division leading to cutaneous neurofibromas and birthmarks.

logo 4png.png